Study #2022-0750
A phase 1/2, open-label, multicenter study of MDK-703 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors (ORCHID-1)
MD Anderson Study Status
Not Accepting
Treatment Agent
MDK-703, Checkpoint Inhibitor, Immune
Description
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic Solid Tumors
Study phase:
Physician name:
Aung Naing
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-996-1481
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.